Cargando…

Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer

BACKGROUND: Immune checkpoint inhibition therapy has been achieved significant success in the treatment of non-small cell lung cancer (NSCLC). However, the role of soluble immune checkpoint- related proteins in NSCLC remains obscure. METHODS: We evaluated the circulating levels of 14 immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qinchuan, He, Yue, Li, Wanlu, Xu, Xiaohang, Hu, Qingfeng, Bian, Zilong, Xu, Andi, Tu, Huakang, Wu, Ming, Wu, Xifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296827/ https://www.ncbi.nlm.nih.gov/pubmed/35874720 http://dx.doi.org/10.3389/fimmu.2022.887916

Ejemplares similares

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
por: Wang, Qinchuan, et al.
Publicado: (2019)

Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins
por: Pan, Sai, et al.
Publicado: (2023)

Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study
por: Wang, Qinchuan, et al.
Publicado: (2020)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
por: Riva, Antonio
Publicado: (2023)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis
por: Liu, Xuefei, et al.
Publicado: (2022)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection
por: Li, Wei, et al.
Publicado: (2022)

Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction
por: Landeira-Viñuela, Alicia, et al.
Publicado: (2022)

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy
por: Chiu, Chris Y., et al.
Publicado: (2023)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2021)

Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection
por: Lee, Nuri, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Risk of Death Associated With Reversion From Prediabetes to Normoglycemia and the Role of Modifiable Risk Factors
por: Cao, Zhi, et al.
Publicado: (2023)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
por: Jiang, Jiehan, et al.
Publicado: (2021)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

Research progress of NF-κB signaling pathway and thrombosis
por: Wang, Zilong, et al.
Publicado: (2023)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
por: Saleh, Reem, et al.
Publicado: (2020)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
por: Zingoni, Alessandra, et al.
Publicado: (2018)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
por: Zhao, Yujie, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression
por: Lima, Hayana Ramos, et al.
Publicado: (2017)

Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value
por: Wu, Shenghui, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors
por: Zhu, Sihui, et al.
Publicado: (2021)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lrbemvqtctvf25kejjqc1jklfi